Literature DB >> 32804464

Successful Treatment of Pandrug-resistant Klebsiella pneumoniae Infection With Ceftazidime-avibactam in a Preterm Infant: A Case Report.

Yesim Coskun1, Serkan Atici2.   

Abstract

Pandrug-resistant (PDR) bacterial infections in intensive care units are emerging as a severe problem. Therefore, new antibiotic options are urgently needed for the treatment of PDR infections in pediatric age groups, especially neonates. Herein, we report a 25 days old preterm neonate successfully treated with ceftazidime-avibactam due to a urinary tract infection caused by PDR Klebsiella pneumoniae. We aimed to describe our experiences about the safety and efficacy of ceftazidime-avibactam treatment.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32804464     DOI： 10.1097/INF.0000000000002807

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  6 in total

1.  Intravenous Ceftazidime-Avibactam in Extremely Premature Neonates With Carbapenem-Resistant Enterobacteriaceae: Two Case Reports.

Authors:  Suzan S Asfour; Faisal A Alaklobi; Adli Abdelrahim; Muhammed Y Taha; Raneem S Asfour; Thanaa M Khalil; Mountasser M Al-Mouqdad
Journal:  J Pediatr Pharmacol Ther       Date:  2022-02-09

2.  Antimicrobial Resistance and Associated Risk Factors of Gram-Negative Bacterial Bloodstream Infections in Tikur Anbessa Specialized Hospital, Addis Ababa.

Authors:  Daniel Beshah; Adey Desta; Gurja Belay; Tamrat Abebe; Solomon Gebreselasie; Tesfaye Sisay Tessema
Journal:  Infect Drug Resist       Date:  2022-08-31       Impact factor: 4.177

Review 3.  Neonatal multidrug-resistant gram-negative infection: epidemiology, mechanisms of resistance, and management.

Authors:  Dustin D Flannery; Kathleen Chiotos; Jeffrey S Gerber; Karen M Puopolo
Journal:  Pediatr Res       Date:  2021-10-01       Impact factor: 3.756

4.  Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against Enterobacterales Clinical Isolates.

Authors:  Renru Han; Xuelin Yang; Yang Yang; Yan Guo; Dandan Yin; Li Ding; Shi Wu; Demei Zhu; Fupin Hu
Journal:  Microbiol Spectr       Date:  2022-01-12

Review 5.  Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients.

Authors:  Helen Giamarellou; Ilias Karaiskos
Journal:  Antibiotics (Basel)       Date:  2022-07-26

Review 6.  Therapeutic Options and Outcomes for the Treatment of Neonates and Preterms with Gram-Negative Multidrug-Resistant Bacteria: A Systematic Review.

Authors:  Lorenzo Chiusaroli; Cecilia Liberati; Maria Caseti; Luigi Rulli; Elisa Barbieri; Carlo Giaquinto; Daniele Donà
Journal:  Antibiotics (Basel)       Date:  2022-08-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.